MAP: A Knowledge-driven Framework for Predicting Single-cell Responses for Unprofiled Drugs

preprint OA: closed
Full text JSON View at publisher
AI-generated deep summary by claude@2026-07, 2026-07-03 · read from full text

The paper introduces MAP, a knowledge-driven framework that predicts single-cell transcriptional responses to chemical perturbations, focusing on zero-shot generalization to unprofiled drugs by leveraging mechanistic relationships rather than treating drugs as isolated identifiers. Using a constructed perturbation-oriented knowledge graph (MAP-KG) that integrates 14 public resources (187k drugs, 23k genes, and 694k mechanistic relationships) and a contrastive pre-training strategy aligning molecular structures, protein sequence features, and textual mechanistic descriptions, the authors generate mechanism-aware gene and drug embeddings coupled to a pretrained single-cell foundation model. MAP is evaluated in two zero-shot regimes, improving top-50 DEG Pearson delta correlation by up to +13.3% for unseen cell type–drug combinations and +12.2% for unprofiled drugs compared with strong baselines, with additional pathway-level GSEA results showing coherent mechanism-consistent programs. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Predicting how cells respond to chemical perturbations is one of the goals for building virtual cells, yet experimentally profiled compounds cover only a small fraction of this space. Existing models struggle to generalize to unprofiled compounds, as they typically treat drugs as isolated identifiers without encoding their mechanistic relationships. We present MAP , a framework that integrates structured biological knowledge into cellular perturbation modeling and supports zero-shot prediction for small molecules with scarce or absent perturbation profiles. Specifically: (i) we construct MAP-KG , a large-scale knowledge graph tailored for cellular perturbation modeling that unifies 14 public resources, spanning 187k drugs, 23k genes, and 694k mechanistic relationships; (ii) we propose a knowledge-driven pre-training strategy that aligns molecular structures, protein sequence features, and textual mechanistic descriptions into a unified embedding space via contrastive learning, producing mechanism-aware and transferable gene and compound embeddings. The resulting knowledge-informed gene and drug representations are then coupled with a pretrained single-cell foundation model to condition perturbation response prediction; (iii) we evaluate MAP under two zero-shot generalization regimes: unseen cell type–drug combinations and the stricter setting of unprofiled drugs, where it improves top-50 DEG Pearson delta correlation by up to +13.3% and +12.2%, respectively, over the strongest baselines across three benchmarks. We further perform pathway-level functional analysis via GSEA for in-silico screening, where MAP predicts coherent, mechanism-consistent programs on unprofiled candidate drugs, and prioritizes 4 of 5 approved anti-cancer drugs in A-549 (non–small cell lung cancer).
Full text 1,887 characters · extracted from oa-doi-fallback · click to expand
Abstract Predicting how cells respond to chemical perturbations is one of the goals for building virtual cells, yet experimentally profiled compounds cover only a small fraction of this space. Existing models struggle to generalize to unprofiled compounds, as they typically treat drugs as isolated identifiers without encoding their mechanistic relationships. We present MAP, a framework that integrates structured biological knowledge into cellular perturbation modeling and supports zero-shot prediction for small molecules with scarce or absent perturbation profiles. Specifically: (i) we construct MAP-KG, a large-scale knowledge graph tailored for cellular perturbation modeling that unifies 14 public resources, spanning 187k drugs, 23k genes, and 694k mechanistic relationships; (ii) we propose a knowledge-driven pre-training strategy that aligns molecular structures, protein sequence features, and textual mechanistic descriptions into a unified embedding space via contrastive learning, producing mechanism-aware and transferable gene and compound embeddings. The resulting knowledge-informed gene and drug representations are then coupled with a pretrained single-cell foundation model to condition perturbation response prediction; (iii) we evaluate MAP under two zero-shot generalization regimes: unseen cell type–drug combinations and the stricter setting of unprofiled drugs, where it improves top-50 DEG Pearson delta correlation by up to +13.3% and +12.2%, respectively, over the strongest baselines across three benchmarks. We further perform pathway-level functional analysis via GSEA for in-silico screening, where MAP predicts coherent, mechanism-consistent programs on unprofiled candidate drugs, and prioritizes 4 of 5 approved anti-cancer drugs in A-549 (non–small cell lung cancer). Competing Interest Statement The authors have declared no competing interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00